Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 12/2022

20-09-2022 | Ulcerative Colitis | Multicenter Seminars: IBD (MUSE: IBD)

An Old Bridge to the Newer Biologics: Cyclosporine for Rescue Therapy in Acute Severe Ulcerative Colitis

Authors: Divya Ashat, Animesh Jain, Kimberly N. Weaver, Millie D. Long, Hans H. Herfarth, Edward L. Barnes

Published in: Digestive Diseases and Sciences | Issue 12/2022

Login to get access

Excerpt

A 45-year-old man with an 11-year history of extensive ulcerative colitis (UC) was evaluated for acute severe UC (ASUC), manifest as increased stool frequency, urgency, hematochezia, and left-sided abdominal pain. He had previously been well-controlled with vedolizumab infusions every 4 weeks for 2 years, but he self-discontinued this therapy in the setting of clinical and endoscopic remission. Therapies utilized prior to vedolizumab included infliximab and azathioprine combination therapy (initiated during a prior admission for ASUC) that were discontinued due to loss of insurance. …
Literature
1.
Loftus CG, Egan LJ, Sandborn WJ. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin N Am 2004;33:vii.
2.
Rubin DT, Ananthakrishnan AN, Siegel CA et al. ACG Clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019;114:384–413.CrossRefPubMed
3.
Barberio B, Black CJ, Savarino EV, Ford AC. Ciclosporin or infliximab as rescue therapy in acute glucorticosteroid-refractory ulcerative colitis: systematic review and network meta-analysis. J Crohns Colitis 2021;15:733–741.CrossRefPubMed
4.
Szántó K, Molnár T, Farkas K. New promising combo therapy in inflammatory bowel diseases refractory to anti-TNF agents: cyclosporine plus vedolizumab. J Crohns Colitis 2018;12:629.CrossRefPubMed
5.
Christensen B, Gibson PR, Micic D et al. Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease. Clin Gastroenterol Hepatol 2019;17:486–493.CrossRefPubMed
6.
Pellet G, Stefanescu C, Carbonnel F et al. Efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab in patients with refractory ulcerative colitis. Clin Gastroenterol Hepatol 2019;17:494–501.CrossRefPubMed
7.
Ollech JE, Dwadasi S, Rai V et al. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2020;51:637–643.CrossRefPubMed
8.
Resál T, Pigniczki D, Szántó K et al. Letter: ciclosporin and vedolizumab for steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2020;52:578–579.CrossRefPubMed
9.
Ganzleben I, Geppert C, Osaba L et al. Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis. Therap Adv Gastroenterol 2020;13:1756284820954112.CrossRefPubMedPubMedCentral
10.
Shaffer SR, Traboulsi C, Krugliak Cleveland N, Rubin DT. Combining cyclosporine with ustekinumab in acute severe ulcerative colitis. ACG Case Rep J 2021;8:e00604.CrossRefPubMedPubMedCentral
11.
Lichtenstein GR, Loftus EV, Isaacs KL et al. ACG Clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018;113:481–517.CrossRefPubMed
12.
Feagan BG, Lasch K, Lissoos T et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019;17:130-138.e137.CrossRefPubMed
13.
Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology 2020;158:1465-1496.e1417.CrossRefPubMed
14.
Click B, Regueiro M. A practical guide to the safety and monitoring of new IBD therapies. Inflamm Bowel Dis 2019;25:831–842.CrossRefPubMed
15.
Weisshof R, Ollech JE, El Jurdi K et al. Ciclosporin therapy after infliximab failure in hospitalized patients with acute severe colitis is effective and safe. J Crohns Colitis 2019;13:1105–1110.CrossRefPubMedPubMedCentral
Metadata
Title
An Old Bridge to the Newer Biologics: Cyclosporine for Rescue Therapy in Acute Severe Ulcerative Colitis
Authors
Divya Ashat
Animesh Jain
Kimberly N. Weaver
Millie D. Long
Hans H. Herfarth
Edward L. Barnes
Publication date
20-09-2022
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07682-7

Other articles of this Issue 12/2022

Digestive Diseases and Sciences 12/2022 Go to the issue

FELLOWS AND YOUNG GIS SECTION

Enhancing Collaboration in the Endoscopy Suite: Challenges, Perspectives, and Solutions

Image of the Month

Modified Percutaneous Endoscopic Gastrojejunostomy for Duodenal Fistula

Original Article

Evaluating Outcomes and Misuse in Opioid-Dependent Chronic Pancreatitis Using a State-Mandated Monitoring System

Current Clinical Controversy

Illicit Drug Use and Endoscopy: When Do We Say No?

Original Article

Performance and Interpretation of Hydrogen and Methane Breath Testing Impact of North American Consensus Guidelines

Original Article

Endoscopic Ultrasound-Guided Porto-systemic Pressure Gradient Measurement Correlates with Histological Hepatic Fibrosis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits